Study #2019-0276
Treatment of Immune Checkpoint Inhibitor-Related Colitis with Infliximab or Vedolizumab: A Randomized Trial
MD Anderson Study Status
Enrolling
Treatment Agent
Infliximab, Vedolizumab
Description
This phase I/II trial studies the side effects of infliximab and vedolizumab and to see how well they work in treating inflammation of the colon (colitis) caused by immune checkpoint inhibitor therapy in patients with cancer of the genital and urinary organs (genitourinary) or melanoma. Monoclonal antibodies, such as infliximab or vedolizumab, may help to treat immunotherapy induced colitis/diarrhea. This study may help to identify the optimal treatment strategy for immune checkpoint inhibitor-related colitis in patients with genitourinary cancer or melanoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Melanoma
Study phase:
Physician name:
Yinghong Wang
Department:
Gastroenterology Hepat & Nutr
For general questions about clinical trials:
1-866-406-5024
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.